➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKinsey
Johnson and Johnson
Express Scripts
Mallinckrodt

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,664,231

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,664,231 protect, and when does it expire?

Patent 8,664,231 protects RASUVO and is included in one NDA.

This patent has twenty-nine patent family members in twenty-one countries.

Summary for Patent: 8,664,231
Title:Concentrated methotrexate solutions
Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml. The invention also relates to a ready-made syringe and a carpule containing such a pharmaceutical solution formulation, as well as a pen injector comprising such a carpule and/or a ready-made syringe.
Inventor(s): Will; Heiner (Hamburg, DE)
Assignee: Medac Gesellschaft fuer Klinische Spezialpraepararate mbH (Wedel, DE)
Application Number:12/374,528
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,664,231
Patent Claim Types:
see list of patent claims
Use; Formulation; Device; Dosage form;

Drugs Protected by US Patent 8,664,231

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Medexus RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-001 Jul 10, 2014 RX Yes Yes   Start Trial   Start Trial SUBCUTANEOUS INJECTION OF METHOTREXATE   Start Trial
Medexus RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-002 Jul 10, 2014 RX Yes Yes   Start Trial   Start Trial SUBCUTANEOUS INJECTION OF METHOTREXATE   Start Trial
Medexus RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-003 Jul 10, 2014 RX Yes Yes   Start Trial   Start Trial SUBCUTANEOUS INJECTION OF METHOTREXATE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,664,231

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2006 033 837Jul 21, 2006
PCT Information
PCT FiledJuly 20, 2007PCT Application Number:PCT/EP2007/006491
PCT Publication Date:January 24, 2008PCT Publication Number: WO2008/009476

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Baxter
Harvard Business School
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.